-transparent.png){kind=logo}
Novel non-peptidic neuropeptide Y Y2 receptor antagonists. 2004
Jill A Jablonowski, and
Wenying Chai, and
Xiaobing Li, and
Dale A Rudolph, and
William V Murray, and
Mark A Youngman, and
Scott L Dax, and
Diane Nepomuceno, and
Pascal Bonaventure, and
Timothy W Lovenberg, and
Nicholas I Carruthers
Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA. jjablono@prdus.jnj.com
Through SAR studies of a piperidinylindoline cinnamide HTS lead, the first potent, non-peptide, low molecular weight selective Neuropeptide Y Y2 (NPY Y2) antagonists have been synthesized. The SAR studies around the piperidinyl, the indolinyl, and the cinnamyl moieties are discussed.
Related Publications
Jill A Jablonowski, and
Wenying Chai, and
Xiaobing Li, and
Dale A Rudolph, and
William V Murray, and
Mark A Youngman, and
Scott L Dax, and
Diane Nepomuceno, and
Pascal Bonaventure, and
Timothy W Lovenberg, and
Nicholas I Carruthers
December 2010,
Bioorganic & medicinal chemistry letters,
Jill A Jablonowski, and
Wenying Chai, and
Xiaobing Li, and
Dale A Rudolph, and
William V Murray, and
Mark A Youngman, and
Scott L Dax, and
Diane Nepomuceno, and
Pascal Bonaventure, and
Timothy W Lovenberg, and
Nicholas I Carruthers
August 2009,
Bioorganic & medicinal chemistry letters,
Jill A Jablonowski, and
Wenying Chai, and
Xiaobing Li, and
Dale A Rudolph, and
William V Murray, and
Mark A Youngman, and
Scott L Dax, and
Diane Nepomuceno, and
Pascal Bonaventure, and
Timothy W Lovenberg, and
Nicholas I Carruthers
September 2011,
EJNMMI research,
Jill A Jablonowski, and
Wenying Chai, and
Xiaobing Li, and
Dale A Rudolph, and
William V Murray, and
Mark A Youngman, and
Scott L Dax, and
Diane Nepomuceno, and
Pascal Bonaventure, and
Timothy W Lovenberg, and
Nicholas I Carruthers
June 2012,
Bioorganic & medicinal chemistry letters,
Jill A Jablonowski, and
Wenying Chai, and
Xiaobing Li, and
Dale A Rudolph, and
William V Murray, and
Mark A Youngman, and
Scott L Dax, and
Diane Nepomuceno, and
Pascal Bonaventure, and
Timothy W Lovenberg, and
Nicholas I Carruthers
January 1990,
Annals of the New York Academy of Sciences,
Jill A Jablonowski, and
Wenying Chai, and
Xiaobing Li, and
Dale A Rudolph, and
William V Murray, and
Mark A Youngman, and
Scott L Dax, and
Diane Nepomuceno, and
Pascal Bonaventure, and
Timothy W Lovenberg, and
Nicholas I Carruthers
January 2014,
Bioorganic & medicinal chemistry letters,
Jill A Jablonowski, and
Wenying Chai, and
Xiaobing Li, and
Dale A Rudolph, and
William V Murray, and
Mark A Youngman, and
Scott L Dax, and
Diane Nepomuceno, and
Pascal Bonaventure, and
Timothy W Lovenberg, and
Nicholas I Carruthers
August 2001,
IDrugs : the investigational drugs journal,
Jill A Jablonowski, and
Wenying Chai, and
Xiaobing Li, and
Dale A Rudolph, and
William V Murray, and
Mark A Youngman, and
Scott L Dax, and
Diane Nepomuceno, and
Pascal Bonaventure, and
Timothy W Lovenberg, and
Nicholas I Carruthers
February 2008,
British journal of pharmacology,
Jill A Jablonowski, and
Wenying Chai, and
Xiaobing Li, and
Dale A Rudolph, and
William V Murray, and
Mark A Youngman, and
Scott L Dax, and
Diane Nepomuceno, and
Pascal Bonaventure, and
Timothy W Lovenberg, and
Nicholas I Carruthers
June 1992,
European journal of biochemistry,
Jill A Jablonowski, and
Wenying Chai, and
Xiaobing Li, and
Dale A Rudolph, and
William V Murray, and
Mark A Youngman, and
Scott L Dax, and
Diane Nepomuceno, and
Pascal Bonaventure, and
Timothy W Lovenberg, and
Nicholas I Carruthers
November 2004,
Current medicinal chemistry,
